Corient Capital Partners, LLC Biomarin Pharmaceutical Inc Transaction History

Corient Capital Partners, LLC

  • $1.34 Billion
  • Q3 2022

A detailed history of Corient Capital Partners, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Corient Capital Partners, LLC holds 3,126 shares of BMRN stock, worth $220,633. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,126
Previous 3,126 -0.0%
Holding current value
$220,633
Previous $259,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$71.48 - $86.85 $37,884 - $46,030
530 Added 20.42%
3,126 $259,000
Q1 2022

May 16, 2022
SELL
$74.28 - $92.69 $7,873 - $9,825
-106 Reduced 3.92%
2,596 $200,000
Q4 2021

Feb 11, 2022
SELL
$71.72 - $91.47 $8,821 - $11,250
-123 Reduced 4.35%
2,702 $239,000
Q3 2021

Nov 16, 2021
BUY
$74.77 - $85.47 $15,851 - $18,119
212 Added 8.11%
2,825 $218,000
Q2 2021

Aug 16, 2021
BUY
$75.51 - $84.79 $197,307 - $221,556
2,613 New
2,613 $218,000
Q1 2021

May 17, 2021
SELL
$74.73 - $90.69 $171,281 - $207,861
-2,292 Closed
0 $0
Q4 2020

Feb 12, 2021
BUY
$72.61 - $90.2 $166,422 - $206,738
2,292 New
2,292 $201,000
Q3 2020

Nov 16, 2020
SELL
$71.87 - $131.03 $715,465 - $1.3 Million
-9,955 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$79.55 - $124.22 $151,065 - $235,893
1,899 Added 23.57%
9,955 $1.23 Million
Q1 2020

May 06, 2020
BUY
$71.37 - $96.85 $574,956 - $780,223
8,056 New
8,056 $680,000

Others Institutions Holding BMRN

# of Institutions
632
Shares Held
185M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Corient Capital Partners, LLC Portfolio

Follow Corient Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corient Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corient Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email